Pancreatic Cancer Research

ResearcherKansai Medical UniversityNo recent work listed

A‐Hon Kwon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-5254-3511; OpenAlex author ID A5108693966, A5108755769. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
63
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 3 papers · 2014: 4 papers · 2015: 3 papers · 2016: 1 paper

Papers 17

  1. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Co-author DOI 10.1016/j.surg.2016.02.032↗
  2. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Last author DOI 10.1007/s11605-014-2637-7↗
  3. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗
  4. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center r… Co-author DOI 10.1016/j.pan.2015.09.008↗
  5. Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy: survival benefit? Last author DOI 10.1002/jhbp.119↗
  6. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Co-author DOI 10.1002/jhbp.130↗
  7. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2323-6↗
  8. Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000125↗
  9. Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model. Last author DOI 10.1007/s00534-012-0576-9↗
  10. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments:… Co-author DOI 10.1007/s00534-013-0616-0↗
  11. The similarity of Type 1 autoimmune pancreatitis to pancreatic ductal adenocarcinoma with significant IgG4-positive plasma cell infiltration. Co-author DOI 10.1007/s00535-012-0677-x↗
  12. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. Last author DOI 10.1007/s11605-011-1795-0↗
  13. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. Last author DOI 10.1016/j.jss.2010.09.027↗
  14. Long-term results of surgical resection after preoperative chemoradiation in patients with pancreatic cancer. Last author DOI 10.1097/mpa.0b013e318229758f↗
  15. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Last author DOI 10.1097/mpa.0b013e3182373a66↗
  16. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderlin… Last author DOI 10.1097/mpa.0b013e3182056b1c↗
  17. The role of circulating dendritic cells in patients with unresectable pancreatic cancer. Last author PMID 22110205↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 17 shared papers, 2011–2016 · strength 0.57
  2. Hiroaki Yanagimoto · 13 shared papers, 2011–2015 · strength 0.43
  3. Tomohisa Yamamoto · 11 shared papers, 2011–2015 · strength 0.36
  4. So Yamaki · 8 shared papers, 2011–2015 · strength 0.27
  5. Satoshi Hirooka · 8 shared papers, 2011–2015 · strength 0.27
  6. Masayuki Sho · 6 shared papers, 2013–2016 · strength 0.23
  7. Hiroki Yamaue · 5 shared papers, 2013–2016 · strength 0.18
  8. Yoshiyuki Nakajima · 4 shared papers, 2013–2016 · strength 0.16
  9. Seiko Hirono · 4 shared papers, 2013–2016 · strength 0.15
  10. Songtae Kim · 4 shared papers, 2012–2014 · strength 0.14
  11. Jun Yamao · 4 shared papers, 2012–2014 · strength 0.14
  12. Yoshiaki Murakami · 3 shared papers, 2015–2016 · strength 0.12
  13. Masanao Kurata · 3 shared papers, 2015–2016 · strength 0.12
  14. Kenichiro Uemura · 3 shared papers, 2015–2016 · strength 0.12
  15. Takumi Fukumoto · 3 shared papers, 2015–2016 · strength 0.12
  16. Ippei Matsumoto · 3 shared papers, 2015–2016 · strength 0.12
  17. Michiaki Unno · 3 shared papers, 2015–2016 · strength 0.12
  18. Fuyuhiko Motoi · 3 shared papers, 2015–2016 · strength 0.12
  19. Goro Honda · 3 shared papers, 2015–2016 · strength 0.12
  20. Manabu Kawai · 3 shared papers, 2014–2016 · strength 0.12
  21. Takahiro Akahori · 2 shared papers, 2015 · strength 0.08
  22. Minako Nagai · 2 shared papers, 2015 · strength 0.08
  23. Ken‐ichi Okada · 2 shared papers, 2014–2016 · strength 0.08
  24. Masaji Tani · 2 shared papers, 2014–2015 · strength 0.07
  25. Keita Wada · 2 shared papers, 2011–2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.